Financial Data and Key Metrics Changes - The company reported revenue of $321 million, down 4% due to a $52 million impact from portfolio transitions, but up 13% organically excluding CSL [8][16] - Adjusted EPS grew 8% to $1.10, driven by strong growth in the base business and share buybacks [8][19] - Adjusted gross margin reached 60.8%, up 550 basis points year over year, supported by technology benefits and a favorable product mix [18][19] Business Line Data and Key Metrics Changes - The hospital business generated $140 million in revenue, up 4% reported and organically, with Blood Management Technologies growing 14% [10][12] - Plasma revenue was $130 million, down 4% reported but up 29% organically, driven by technology upgrades and a one-time revenue benefit from a software agreement [12][14] - Interventional technologies declined 7% due to tough comparisons from prior year OEM destocking [11][12] Market Data and Key Metrics Changes - The U.S. plasma collection volume grew in the low single digits, with expectations for modest recovery in the back half of the fiscal year [13][82] - The company maintains an 80% market share in plasma DMS software, reinforcing its competitive position [13][30] Company Strategy and Development Direction - The company is focused on strengthening its core products: plasma, hemostasis management, and vascular closure, which are expected to drive revenue growth and margin expansion [23][24] - Strategic initiatives include leadership additions, organizational realignment, and targeted commercial initiatives to enhance execution in interventional technologies [9][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance, with expectations for low double-digit compounded annual growth in revenue and mid-20s adjusted EPS CAGR [22][23] - The company anticipates stronger cash generation and reaffirmed full-year free cash flow guidance of $160 million to $200 million [21][22] Other Important Information - The company completed $225 million in share buybacks last year and has authorized a new $500 million program for the next three years [75] - The adjusted income tax rate was 24.9% in the quarter, up from 19.9% the previous year, reflecting lower benefits from performance share vestings [19] Q&A Session Summary Question: Can you provide details on the drivers of strong plasma performance? - Management highlighted innovation in pricing and share gains, with half of the 29% growth attributed to a software agreement [28][30] Question: What is the growth rate for MVP and MVP XL in vascular closure? - MVP and MVP XL saw roughly 6% growth, with challenges noted in the legacy Vascade product [34][36] Question: What is the outlook for U.S. plasma collections? - Management indicated a possibility of low single-digit growth in the back half of the year, with ongoing share gains expected [82][84] Question: How is the company addressing increased competition in interventional technologies? - The company is enhancing its sales and marketing efforts, reorganizing teams, and focusing on execution to regain competitiveness [71][72] Question: What is the company's appetite for further M&A? - Management stated that M&A is off the table in the near term, focusing instead on improving existing business performance [76]